Advertisement
Screener

ProPhase Labs, Inc. (PRPH) Increase (Decrease) in Other Current Liabilities

2.8 / 5 stars · 68/120 Roast Me

ProPhase Labs, Inc. Increase (Decrease) in Other Current Liabilities

ProPhase Labs, Inc. (PRPH) reported Increase (Decrease) in Other Current Liabilities of $611.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2024-03-29

  • ProPhase Labs, Inc. increase (decrease) in other current liabilities for the quarter ending 2023-12-31 was $641.00K.
  • ProPhase Labs, Inc. increase (decrease) in other current liabilities for the quarter ending 2023-09-30 was -$315.00K, a 118.77% decline year-over-year.
  • ProPhase Labs, Inc. increase (decrease) in other current liabilities for the quarter ending 2023-06-30 was -$3.75M.
  • ProPhase Labs, Inc. increase (decrease) in other current liabilities for the quarter ending 2023-03-31 was $4.04M, a 424.29% increase year-over-year.
  • ProPhase Labs, Inc. increase (decrease) in other current liabilities for fiscal 2023 was $611.00K.
  • ProPhase Labs, Inc. increase (decrease) in other current liabilities for fiscal 2022 was -$423.00K.
  • ProPhase Labs, Inc. increase (decrease) in other current liabilities for fiscal 2021 was -$2.83M, a 255.84% decline from fiscal 2020.
  • ProPhase Labs, Inc. increase (decrease) in other current liabilities for fiscal 2020 was $1.81M.
Period endIncrease (Decrease) in Other Current Liabilities 3 monthIncrease (Decrease) in Other Current Liabilities 6 monthIncrease (Decrease) in Other Current Liabilities 6 month as first filedIncrease (Decrease) in Other Current Liabilities 9 monthIncrease (Decrease) in Other Current Liabilities 9 month as first filedIncrease (Decrease) in Other Current Liabilities 12 month
2023-12-31$641.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$326.00K
derived: sum of 2 quarters · filed 2024-03-29
-$3.43M
derived: sum of 3 quarters · filed 2024-03-29
$611.00K
10-K · filed 2024-03-29
2023-09-30-$315.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$4.07M
derived: sum of 2 quarters · filed 2023-11-13
-$30.00K
10-Q · filed 2023-11-13
-$1.15M
derived: sum of 4 quarters · filed 2024-03-29
2023-06-30-$3.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
$285.00K
10-Q · filed 2023-08-11
-$838.00K
derived: sum of 3 quarters · filed 2024-03-29
$840.00K
derived: sum of 4 quarters · filed 2024-03-29
2023-03-31$4.04M
10-Q · filed 2023-05-12
$2.91M
derived: sum of 2 quarters · filed 2024-03-29
$4.59M
derived: sum of 3 quarters · filed 2024-03-29
$2.84M
derived: sum of 4 quarters · filed 2024-03-29
2022-12-31-$1.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$555.00K
derived: sum of 2 quarters · filed 2024-03-29
-$1.19M
derived: sum of 3 quarters · filed 2024-03-29
-$423.00K
10-K · filed 2024-03-29
2022-09-30$1.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$70.00K
derived: sum of 2 quarters · filed 2023-11-13
$700.00K
10-Q · filed 2023-11-13
-$835.00K
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$1.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
-$978.00K
10-Q · filed 2023-08-11
-$2.51M
derived: sum of 3 quarters · filed 2023-08-11
-$8.00M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31$770.00K
10-Q · filed 2023-05-12
-$765.00K
derived: sum of 2 quarters · filed 2023-05-12
-$6.25M
derived: sum of 3 quarters · filed 2023-05-12
-$9.88M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$1.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29
-$7.02M
derived: sum of 2 quarters · filed 2023-03-29
-$10.64M
derived: sum of 3 quarters · filed 2023-03-29
-$2.83M
10-K · filed 2023-03-29
2021-09-30-$5.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$9.11M
derived: sum of 2 quarters · filed 2022-11-10
-$1.29M
10-Q · filed 2022-11-10
-$313.00K
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$3.63M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
$4.19M
10-Q · filed 2022-08-12
$5.17M
derived: sum of 3 quarters · filed 2022-08-12
$5.98M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31$7.82M
10-Q · filed 2022-05-13
$8.80M
derived: sum of 2 quarters · filed 2022-05-13
$9.61M
derived: sum of 3 quarters · filed 2022-05-13
$9.70M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31$979.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$1.79M
derived: sum of 2 quarters · filed 2022-03-31
$1.88M
derived: sum of 3 quarters · filed 2022-03-31
$1.81M
10-K · filed 2022-03-31
2020-09-30$809.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$904.00K
derived: sum of 2 quarters · filed 2021-11-12
$835.00K
10-Q · filed 2021-11-12
$860.00K
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30$95.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13
$26.00K
10-Q · filed 2021-08-13
$51.00K
derived: sum of 3 quarters · filed 2021-08-13
-$21.00K
derived: sum of 4 quarters · filed 2021-08-13
2020-03-31-$69.00K
10-Q · filed 2021-05-14
-$44.00K
derived: sum of 2 quarters · filed 2021-05-14
-$116.00K
derived: sum of 3 quarters · filed 2021-05-14
-$61.00K
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31$25.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31
-$47.00K
derived: sum of 2 quarters · filed 2021-03-31
$8.00K
derived: sum of 3 quarters · filed 2021-03-31
-$247.00K
10-K · filed 2021-03-31
2019-09-30-$72.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-19
-$17.00K
derived: sum of 2 quarters · filed 2020-11-19
-$272.00K
10-Q · filed 2020-11-19
$144.00K
derived: sum of 4 quarters · filed 2020-11-19
2019-06-30$55.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11
-$200.00K
10-Q · filed 2020-08-11
$216.00K
derived: sum of 3 quarters · filed 2020-08-11
-$435.00K
derived: sum of 4 quarters · filed 2020-08-11
2019-03-31-$255.00K
10-Q · filed 2020-05-12
$161.00K
derived: sum of 2 quarters · filed 2020-05-12
-$490.00K
derived: sum of 3 quarters · filed 2020-05-12
-$585.00K
derived: sum of 4 quarters · filed 2020-05-12
2018-12-31$416.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26
-$235.00K
derived: sum of 2 quarters · filed 2020-03-26
-$330.00K
derived: sum of 3 quarters · filed 2020-03-26
-$225.00K
10-K · filed 2020-03-26
2018-09-30-$651.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$746.00K
derived: sum of 2 quarters · filed 2019-11-12
-$641.00K
10-Q · filed 2019-11-12
-$712.00K
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30-$95.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12
$10.00K
10-Q · filed 2019-08-12
-$61.00K
derived: sum of 3 quarters · filed 2019-08-12
-$28.00K
derived: sum of 4 quarters · filed 2019-08-12
2018-03-31$105.00K
10-Q · filed 2019-05-14
$34.00K
derived: sum of 2 quarters · filed 2019-05-14
$67.00K
derived: sum of 3 quarters · filed 2019-05-14
-$3.80M
derived: sum of 4 quarters · filed 2019-05-14
2017-12-31-$71.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26
-$38.00K
derived: sum of 2 quarters · filed 2019-03-26
-$3.91M
derived: sum of 3 quarters · filed 2019-03-26
-$1.49M
10-K · filed 2019-03-26
2017-09-30$33.00K
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14
-$3.83M
derived: sum of 2 quarters · filed 2018-11-14
-$1.42M
10-Q · filed 2018-11-14
-$67.00K
10-Q · filed 2017-11-13
2017-06-30-$3.87M
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20
-$1.45M
10-Q/A · filed 2018-08-20
-$100.00K
10-Q · filed 2017-08-11
2017-03-31$2.42M
10-Q/A · filed 2018-08-20
2016-09-30$618.00K
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-08-20
-$375.00K
derived: sum of 2 quarters · filed 2018-08-20
$22.00K
10-Q/A · filed 2018-08-20
2016-06-30-$993.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20
-$596.00K
10-Q/A · filed 2018-08-20
2016-03-31$397.00K
10-Q/A · filed 2018-08-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Pulmatrix, Inc. (PULM)United States$0.006B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26